Total deal worth KRW 7 billion notamment upfront KRW 1 billion + étapes clés... Technology transfer of traitement des lésions cornéennes candidate 'RCI001U' national production and commercialization rights... essai clinique de Phase 1 planned cette année
RudaCure a annoncé le 16th that it a signé a concession de licence accord worth KRW 7 billion with Hanlim Pharmaceutical for the ulcère cornéen and traitement des lésions cornéennes candidate 'RCI001U.'
Under the accord, RudaCure will receive a total of KRW 7 billion from Hanlim Pharmaceutical, notamment an upfront payment of KRW 1 billion plus étapes clés tels que clinical approvals. Hanlim Pharmaceutical will hold national production and commercialization rights for RCI001U. RudaCure will receive double-digit royalties after commercialization.
Both companies plan to enter essais cliniques de Phase 1 for RCI001U within cette année to expedite commercialization.
RCI001U is a pipeline derived from RCI001, RudaCure's existing traitement de la sécheresse oculaire candidate, the Rac1 inhibitor actuellement in development. This follows RudaCure's transfert de technologie of the traitement de la sécheresse oculaire candidate RCI001 to Hanlim Pharmaceutical in 2021, with this deal covering an additional indication.
Selon RudaCure, given that treatment drugs for lésions cornéennes are actuellement limited nationalally, the transfert de technologie of RCI001U is being made after completing third-party confirmatory efficacy testing and études toxicologiques non cliniques.
A RudaCure representative a déclaré : "Grâce à cela additional indication accord de transfert de technologie, we have strengthened our network with Hanlim Pharmaceutical," adding, "We expect continuous collaboration to develop not only sécheresse oculaire and traitement des lésions cornéenness, but also divers ophtalmique treatments notamment ocular implants for macular degeneration."
